https://www.avient.com/knowledge-base/article/how-lightweight-automotive-components?rtype[]=1164
2.
https://www.avient.com/knowledge-base/article/how-lightweight-automotive-components?sust[]=1165
2.
https://www.avient.com/knowledge-base/article/continuous-fiber-reinforced-thermoplastic-composites?ind[]=6595
The graph above shows the result of tensile load applied longitudinally to three laminate samples made with Polystrand™ continuous glass fiber reinforced polypropylene in 2-, 4- and 6-ply configurations, illustrated below.
https://www.avient.com/knowledge-base/article/how-lightweight-automotive-components
2.
https://www.avient.com/sites/default/files/2022-04/Avient Announces Agreement to Acquire Dyneema_0.pdf
Further, Avient’s composites
platform with the Dyneema business will represent over 50% of the company’s Specialty
Engineered Materials segment sales.
2
“In conjunction with our intent to acquire Dyneema, we plan to explore a potential sale of our
distribution business,” said Mr.
https://www.avient.com/sites/default/files/2022-07/MEVOPUR Chemical Foaming Agents Application Bulletin_CN.pdf
在不限制本声明的一般性的情况下，不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用：
(1) 接触人体组织或体液长达30天或更长时间；
(2)“整形”（整容或重建）手术；
(3) 生殖植入物或任何节育器械；或者
(4) 用于支持或维持人类生命的永久性（超过30天）植入式医疗器械中的任何关键组件。
https://www.avient.com/sites/default/files/2022-05/Compensation Committee Charter (REV 10-2019).pdf
Develop and maintain a competitive executive compensation program in order to attract and
retain qualified executives and to provide incentives to management that reward pay for
performance in attaining the Company’s goals and objectives.
2
• Review and approve a peer group of companies to be used for marketplace trend analysis and
to assess the competitiveness of the Company’s total compensation opportunities for
executive officers
https://www.avient.com/sites/default/files/2022-07/REMAFIN EP White Masterbatches for Pharma Application Bulletin_CN.pdf
在不限制本声明的一般性的情况下，不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用：
(1) 接触人体组织或体液长达30天或更长时间；
(2)“整形”（整容或重建）手术；
(3) 生殖植入物或任何节育器械；或者
(4) 用于支持或维持人类生命的永久性（超过30天）植入式医疗器械中的任何关键组件。
https://www.avient.com/sites/default/files/2021-09/mevopur-colors-for-needle-hubs-bulletin-cn.pdf
在不限制本声明的一般性的情况下，不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用：
(1) 接触人体组织或体液长达30天或更长时间；
(2)“整形”（整容或重建）手术；
(3) 生殖植入物或任何节育器械；或者
(4) 用于支持或维持人类生命的永久性（超过30天）植入式医疗器械中的任何关键组件。
https://www.avient.com/sites/default/files/2022-05/MEVOPUR LQ for Silicone Elastomers_CN.pdf
在不限制本声明的一般性的情况下，不得将埃万特的产品用于旨在用于以下目的的任何医疗器械应用：
(1) 接触人体组织或体液长达30天或更长时间；
(2)“整形”（整容或重建）手术；
(3) 生殖植入物或任何节育器械；或者
(4) 用于支持或维持人类生命的永久性（超过30天）植入式医疗器械中的任何关键组件。